AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Aclarion shares surge 21.28% intraday after Nociscan featured in IJSS special pain issue with case study success.
ByAinvest
Thursday, Dec 4, 2025 9:50 am ET1min read
Aclarion (NASDAQ: ACON) surged 21.28% intraday after multiple news events highlighted its Nociscan solution being featured in the International Journal of Spine Surgery (IJSS) and a record 89% year-over-year increase in Nociscan scan volumes for Q3 2025. The journal publication, a prominent peer-reviewed platform, showcased a successful case study where Nociscan enabled precise diagnosis of chronic low back pain, validating its clinical utility. The technology, described as the first evidence-supported SaaS platform for noninvasive lumbar disc pain assessment, was praised for improving surgical targeting and patient outcomes. The scan volume growth and journal recognition collectively reinforced investor confidence in Aclarion’s market potential and technological differentiation, driving the sharp intraday rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet